Neurogene
NGNE
55 hedge funds and large institutions have $241M invested in Neurogene in 2019 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 9 increasing their positions, 13 reducing their positions, and 10 closing their positions.
349% more capital invested
Capital invested by funds: $53.7M → $241M (+$188M)
190% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 10
53% more funds holding
Funds holding: 36 → 55 (+19)
23% more call options, than puts
Call options by funds: $777K | Put options by funds: $632K
1.33% less ownership
Funds ownership: 3.35% → 2.01% (-1.3%)
31% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
+$9.57M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$8.22M |
| 3 |
BC
Boxer Capital
San Diego,
California
|
+$5.03M |
| 4 |
O
OrbiMed
New York
|
+$4.48M |
| 5 |
PA
Perceptive Advisors
New York
|
+$2.49M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$39.4M |
| 2 |
Millennium Management
New York
|
-$1.8M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$1.15M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$657K |
| 5 |
Two Sigma Investments
New York
|
-$262K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Citigroup
New York
| $78K | +$6.67K | +67 | +27% |
|
52
UBS Group
Zurich,
Switzerland
| $49K | -$5.28K | -53 | -21% |
|
53
Morgan Stanley
New York
| $31K | +$2.49K | +25 | +25% |
|
54
Bank of Montreal
Toronto,
Ontario, Canada
| $15K | – | – | – |
|
|
GWM
55
Geneos Wealth Management
Englewood,
Colorado
| $2K | +$1.1K | +11 | New |
|
|
56
T. Rowe Price Associates
Baltimore,
Maryland
| – | -$1.15M | -20,196 | Closed |
|
|
OAM
57
Oxford Asset Management
Oxford,
United Kingdom
| – | -$148K | -2,589 | Closed |
|
|
DCM
58
Driehaus Capital Management
Chicago,
Illinois
| – | -$143K | -2,500 | Closed |
|
59
TD Asset Management
Toronto,
Ontario, Canada
| – | -$59K | -1,029 | Closed |
|
|
VF
60
Virtu Financial
New York
| – | -$57K | -998 | Closed |
|
61
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$28K | -494 | Closed |
|
|
TRCT
62
Tower Research Capital (TRC)
New York
| – | -$22K | -395 | Closed |
|
|
TC
63
Truvestments Capital
Sarasota,
Florida
| – | -$6K | -113 | Closed |
|
64
Simplex Trading
Chicago,
Illinois
| – | -$5.38K | -54 | Closed |
|
NGNE Hedge Fund Activity: Q4 2019 in Review
55 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Neurogene (NGNE) for Q4 2019, worth a combined $241M — up 349% from $53.7M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new NGNE positions and 10 closed out — a net gain of 19 holders — while 9 added to existing stakes and 13 trimmed.
The largest buyer was Redmile Group, opening a new position worth an estimated $9.57M. The largest seller was Baker Bros. Advisors, cutting an estimated $39.4M.
- 55 institutional investors held Neurogene (NGNE) as of Q4 2019, up from 36 in Q3 2019.
- Funds reported $241M of Neurogene stock for Q4 2019, up 349% quarter-over-quarter.
- 29 funds opened new Neurogene positions in Q4 2019 and 10 closed out, a net change of +19 holders.
- The largest Neurogene buyer in Q4 2019 was Redmile Group, an estimated $9.57M added.
- The largest Neurogene seller in Q4 2019 was Baker Bros. Advisors, an estimated $39.4M sold.
Based on aggregated 13F filings for Q4 2019.